Renaissance Capital logo

PPD Priced, Nasdaq: PPD

LBO'd contract research organization that provides drug development services.

Industry: Health Care

Latest Trade: $34.90 0.00 (0.0%)

First Day Return: +11.1%

Return from IPO: +29.3%

Industry: Health Care

We are a leading provider of drug development services to the biopharmaceutical industry, focused on helping our customers bring their new medicines to patients around the world. We have been in the drug development services business for more than 30 years, providing a comprehensive suite of clinical development and laboratory services to pharmaceutical, biotechnology, medical device and government organizations, as well as other industry participants. Over that time, we have developed a track record of consistent quality, delivery and continuous innovation that has enabled us to grow faster than our underlying market over the past five years and deliver strong financial results. In 2018, we served all of the top 50 biopharmaceutical companies in the world, as ranked by 2018 research and development spending, and were involved in 66 drug approvals. We also participated in the development of all of 2018's top ten selling drugs, as ranked by 2018 revenue. Since 2014, we have also worked with over 300 companies in the growing biotechnology sector through our PPD Biotech model, which was built specifically to serve the unique needs of this customer segment.
more less
IPO News for PPD
more
IPO Data
IPO File Date 01/09/2020
Offer Price $27.00
Price Range $24.00 - $27.00
Offer Shares (mm) 60.0
Deal Size ($mm) $1,620
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 02/05/2020
Offer Price $27.00
Price Range $24.00 - $27.00
Offer Shares (mm) 60.0
Deal Size ($mm) $1,620
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters Wilmington, NC
Founded 1985
Employees 23,000
Website www.ppdi.com